The dangerous window is not award day; it is the two weeks when sales pushes stock while legal still has the pre-VBP playbook open. This article provides healthcare and pharmaceutical counsel with a statutory and practical framework for restructuring distributor contracts in the fourteen days after a volume-based procurement award, including contract modification principles, anti-bribery safeguards and a six-column risk heatmap for evaluating every affected agreement.
What changes when the award lands
A volume-based procurement award is a discontinuity in the commercial relationship, not an incremental change. The winning product receives guaranteed hospital purchase volumes at a substantially reduced price, while losing products are pushed out of the tendered hospitals or face steep volume loss. For the distributor network, the award changes the economics of every agreement that touches the winning SKUs: the margin assumptions collapse, the sales push intensifies, and the contractual provisions drafted for the old price regime suddenly determine who bears the loss. In-house counsel who wait for the first dispute to look at the contracts will find that the dispute was decided by the silence in the agreements.
The fourteen-day window matters because it is the period during which the company can still act on the contracts without the pressure of an existing dispute. After the window, sales teams will have pushed inventory, distributors will have demanded price adjustments, and hospitals will have begun reconciling tendered volumes. Each of those events hardens a position. The heatmap described below is the tool that lets counsel evaluate the entire portfolio quickly and decide which agreements need modification, which need termination and which can be left alone.
- When the award lands, every distributor clause is either heat
- (renegotiate) or ice (stable)
- HEAT CLAUSES
- Price & rebate grids
- VBP price breaks prior economics
Statutory framework
Civil Code contract provisions
The PRC Civil Code provides the two principal legal tools for VBP-related contract work. Article 509 requires parties to perform their obligations in good faith and to observe the principle of good faith in exercising their rights and performing their obligations, which supports the obligation to cooperate in implementing price adjustments even where the contract is silent. Article 533 establishes the change of circumstances doctrine: where the foundation of the contract undergoes a material change that was unforeseeable at the time of signing, and the change makes continued performance manifestly unfair, the affected party may renegotiate with the other party, and if negotiation fails, may request a court or arbitration body to modify or terminate the contract. The VBP award, with its mandatory price reduction and volume commitment, is the paradigmatic case of a material change of circumstances in the pharmaceutical distribution context.
"Article 533 of the PRC Civil Code: After the contract is concluded, where a material change occurs in the objective circumstances which was not foreseeable at the time of conclusion and is not caused by force majeure, and continuing performance of the contract is manifestly unfair to one party, the affected party may renegotiate with the other party."
Anti-Unfair Competition Law and commercial bribery
The PRC Anti-Unfair Competition Law Article 7 prohibits commercial bribery, including the giving of property or other means to a counterparty's staff or to the party managing transactions in order to obtain a transaction opportunity or competitive advantage. The SAMR Interim Provisions on Prohibiting Commercial Bribery, which came into effect in 2025, detail the scope of prohibited conduct and the factors regulators consider. In the VBP context, the anti-bribery risk spikes because the award compresses margins, and distributors under pressure may resort to improper incentives to maintain hospital purchases or to push volume outside the tendered scope. The heatmap must therefore include an anti-bribery assessment for every distributor relationship, not only the ones that historically raised concerns.
Enforcement context: the SPC change of circumstances case
The Supreme People's Court has recognized that major state policy shifts, including centralized procurement price cuts, can constitute grounds for adjusting or terminating distribution obligations. In a retrial decision published in 2020, the SPC applied the change of circumstances doctrine where a distribution arrangement became manifestly unfair after policy changes altered the market conditions that formed the basis of the contract. The decision is significant because it confirms that distributors cannot simply be held to the old commercial terms after a VBP award, and equally that manufacturers cannot unilaterally rewrite the terms. The correct path is renegotiation, and where renegotiation fails, a judicial modification or termination based on the documented change of circumstances.
- Freeze award terms
- Price, volume, regions, timeline
- Pull all distributor contracts
- Including side letters
- Heat-map each clause
The distributor contract heatmap
The practical deliverable is a six-column evaluation framework applied to every active distribution agreement that touches the winning SKUs. For each agreement, counsel scores the contract on the six dimensions below and assigns a priority: modify, terminate or monitor.
Column 1: Price-adjustment mechanism
Does the agreement contain a mechanism for adjusting the distributor purchase price when the manufacturer's price changes, or when tender pricing applies? Many agreements tie the distributor price to a fixed list price with no adjustment clause, which leaves the manufacturer absorbing the entire VBP margin compression. The ideal provision references tender pricing and provides for automatic alignment or a mandatory renegotiation within a fixed period. The absence of such a mechanism is the most common heatmap failure.
Column 2: Inverted service fee compliance
Does the agreement contemplate any rebate, discount or service fee that could be characterized as an inverted service fee, where the fee paid to the distributor exceeds the value of the services actually provided? The inverted fee structure is a recognized anti-bribery and tax risk. The heatmap should flag any fee arrangement that cannot be substantiated by documented services, and counsel should require the distributor to provide the supporting evidence before any payment is made.
Column 3: Inventory liquidation
What happens to inventory in the distributor's warehouse that was purchased under the old price? The agreement should specify whether the distributor has return rights, whether price protection applies to existing stock, and how near-expiry product is handled. Without a liquidation mechanism, the distributor's demand for compensation becomes an unresolved commercial dispute that blocks the new pricing implementation.
Column 4: Indemnity isolation
Does the agreement isolate each party's liability, or does a single clause expose the manufacturer to all downstream claims? After an award, hospital claims, patient claims and regulator inquiries can all arise from the same product. The indemnity provisions should allocate responsibility for product quality, labelling, distribution handling and regulatory compliance, and should include a notice and defense cooperation mechanism.
Column 5: Rebate audit rights
Does the manufacturer retain the right to audit the distributor's records, including the pricing actually charged to hospitals and the end-user destinations of the product? Audit rights are the practical tool that prevents diversion, grey-market sales and unapproved pricing. The heatmap should flag agreements without audit rights and counsel should obtain them during the modification process.
Column 6: Unilateral exit triggers
Does the agreement allow the manufacturer to exit the relationship without penalty where the distributor fails to comply with tender obligations, engages in bribery or fails to meet the new compliance standards? The exit trigger should be documented as a material breach, with a cure period, and should be paired with a non-compete or transition clause that protects the manufacturer's ability to restructure the channel.
Executing the modification process
For agreements that require modification, counsel should begin with the change of circumstances framework. The notice letter to each distributor should state the VBP award, the price impact, the proposed adjustment and the basis in Article 533, and should invite renegotiation within a defined period. Where the distributor rejects the adjustment, the company's options are documented negotiation, mediation or a judicial modification action, and counsel should preserve the correspondence as evidence of the good-faith renegotiation effort required by the doctrine. Throughout the process, the company should maintain a single tracker of all affected agreements, their heatmap scores, the modification status and the deadlines, so that the fourteen-day window is used deliberately rather than reactively.
The anti-bribery dimension should be integrated into every modification. When a distributor agreement is amended, the amendment should restate the anti-bribery commitments, confirm the substance of any service fees and attach the evidence requirements. The company should also consider a targeted due diligence review of the highest-risk distributors, including ownership checks to identify shell entities or hospital-adjacent individuals. The award creates the commercial pressure that drives misconduct, and the legal function's job is to ensure the contract architecture removes the opportunity before the pressure converts into behaviour.
One structural question deserves early attention: whether the VBP award changes the company's distribution strategy itself. In many tenders, the manufacturer is required to deliver the product to the tendered hospitals directly or through a designated chain, and the traditional distributor network is bypassed for the tendered volumes. When this happens, the legacy distributor agreements covering the same hospitals create overlapping supply obligations, and the company must decide whether to terminate, suspend or convert those agreements. The heatmap should flag every agreement whose territory overlaps the tendered hospitals, because the overlap is where the most damaging disputes occur: the distributor argues it remains entitled to the old volumes, the hospital argues the distributor is not authorized to supply, and the manufacturer is caught between two contracts that both claim the same product flow. The modification or termination decision for overlapping agreements should be made in the fourteen-day window, with the tender documentation and the supply obligations attached to each notice, so that the company speaks with one voice to both the distributor and the hospital.
Read next: VBP & distributor disputes · Exclusive agency termination · Hospital AR
Discussion
Share experience or questions about this topic. This is a public discussion — not legal advice. Do not post confidential case details.
Have a question after reading? Leave it here, or Ask a Lawyer for a free initial consultation.
Comments are moderated. China Legal Portal is a directory and information resource; no attorney–client relationship is formed by posting here.
